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ABSTRACT
The objective of the present work was to investigate the existence of an
oxytocin (OT)-mediated autocrine/paracrine signaling upon small cell
carcinoma of the lung (SCCL) cell growth. In that view, OT receptor
(OTR) expression, concomitant with OT synthesis and secretion, was
evidenced on three different SCCL cell lines (DMS79, H146, and H345)
and related to the vasopressin (VP) system. Specific OT, VP, OTR, V1a VP
receptor (V1aR), and V1b/V3 VP receptor (V1bR/V3R) transcripts were
identified by reverse transcription-PCR in all cell lines studied. Binding of
125I-(d(CH2)51,Tyr(Me)2,Thr4,Orn8,Tyr9-NH2)-vasotocin (OVTA) was ob-
served on all SCCL cell lines, with a Kd (dissociation constant) ranging
from 0.025–0.089 nM, depending on the cell line and the analytical
method. Selectivity of 125I-OVTA binding was confirmed by displacement
curves obtained with various OTR and VP receptor agonists and antag-
onists (OT, OVTA, L-371,257, VP, F180). Immunocytochemistry identi-
fied cellular OT and VP, and peptide secretion was measured in super-
natants of SCCL cultures. [3H]Thymidine incorporations, applied on
H345 cells, demonstrated a dose-dependent mitogenic effect of exogenous
OT (1 and 100 nM) that was abolished by the OTR antagonist OVTA. A
decrease of proliferation was also observed with OVTA alone, showing a
functional mitogenic effect of tumor-derived OT. Taken together, these
observations demonstrate the existence of a functional OT-mediated au-
tocrine/paracrine signaling actively implicated in growth and develop-
ment of SCCL tumors. Furthermore, these findings point to the potential
of OT antagonists for development as therapeutic agents for the treatment
of SCCL.
INTRODUCTION
Of the various types of human lung cancer, SCCL,3 also called
“oat-cell” carcinoma, is one of the most aggressive. In the United
States, SCCL accounts for 20% of all primary lung carcinoma. The
overall cumulative 5-year survival rate is 1%, compared with 12–
25% for other types of lung cancer (1). SCCL is most often associated
with overexpression of VP, a neurohypophysial gene (2). VP overex-
pression leads, in many cases, to an ectopic secretion of VP that
induces a paraneoplastic syndrome with water intoxication, hy-
ponatremia, and hypernatriuria known as Schwartz-Bartter syndrome
(3). High plasma concentrations of VP and associated NP (VP-NP), a
highly conserved 10-kDa domain present in VP precursor (4–10), are
biological hallmarks of this syndrome. However, all neurohypophy-
sial gene-expressing tumors do not secrete peptides. A NP-related
protein is targeted to the outer surface of cell membrane as a NP-
related cell surface antigen (8, 11). In vitro, VP has been shown to
exert trophic and mitogenic effects on various human SCCL cell lines.
This mitogenic effect seems to be mediated by the V1aR (12–15). The
expression by SCCL cell lines of all known VP receptor subtypes
[V1aR, V1bR (also called V3R), and V2R] has been demonstrated by
North et al. (16, 17), suggesting a multifaceted autocrine role of VP
on SCCL growth.
High NP plasma levels are reported in approximately two of three
cases of SCCL (8). The evidence of ectopic secretion is not restricted
only to VP and related NP. High levels of the other neurohypophyseal
hormone OT, together with OT-NP, were measured in plasma of
30–40% of these cases (6, 8, 18), as well as in acetone extracts of
SCCL tumors (5). Nevertheless, up to now, very little is known about
the pathophysiological consequences of OT overexpression and OT
secretion by SCCL on tumor development and patient survival. The
expression of OTR has been demonstrated in breast cancer, in neu-
roblastomas and glial tumors, and in endometrial adenocarcinomas. In
these cases, OT exhibits an OTR-mediated antiproliferative effect on
cancer cells (19–29). On the contrary, an increase of cell proliferation
through an OTR-mediated effect has been demonstrated in human
trophoblast and choriocarcinoma cell lines (30).
Therefore, there was a high interest in assessing the biological role
of OT on SCCL cells. The objective of the present work was to
determine the existence of an OT-mediated autocrine/paracrine sig-
naling upon SCCL cell growth. OTR expression, OT synthesis, and
secretion were investigated on three different SCCL cell lines
(DMS79, H146, and H345). Then, the implication of exogenous and
endogenous OT was assessed on cell proliferation. To characterize the
whole neurohypophyseal peptide system of SCCL cell lines, VP and




DPBS (17-513F), FCS, and RPMI 1640 were purchased from BioWhittaker.
TriPure isolation reagent RNase-free DNase I, complete protease inhibitor
mixture tablet, the Expand Reverse Transcriptase System, and the Expand
Long Template PCR System were purchased from Roche. Other reagents were
Triton X-100 (ICN); Tissue-Tek (Sakura); [3H]dThd (Amersham Pharmacia
Biotech); scintillation liquid (Packard Bioscience); primers, Moloney murine
leukemia virus reverse transcriptase, Taq polymerase, ethidium bromide, and
agarose (Life Technologies, Inc.); and the QIAquick Gel Extraction Kit (Qia-
gen). OT, VP, insulin-transferrin-selenium solution (I-1884), and BSA (BSA
fraction V, A-4503) were obtained from Sigma. OTR ligand was 125I-OVTA
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(New England Nuclear; Ref. 31). OTR antagonists were OVTA (Bachem; Ref.
32) and L-371,257 (kindly provided by L. Koch; Merck Research Laborato-
ries; Ref. 33). The V1aR agonist F180 was kindly provided by P. Riviere
(Ferring Research; Refs. 34 and 35). Glycerol, paraformaldehyde, and meth-
anol were obtained from Merck Eurolabo. Normal goat serum and antihuman
CK mAb MNF116 were obtained from Dako. Abs directed to neurohypoph-
ysial peptides were anti-OT mAb O33 (36), rabbit anti-OT serum (O4; Ref.
37), anti-VP mAb C2.23 (kindly given by A. Burlet; Ref. 38), and rabbit
anti-OT serum (AOS) purchased from Phoenix Pharmaceuticals, Inc. Human
recombinant EGF (E-9644), mouse isotype controls IgG1 (M-5284), IgM
(M-5909), and rabbit immunoglobulin (I-5006) were purchased from Sigma.
Secondary Abs were rhodamine (TRITC)-conjugated Affinipure goat antirab-
bit IgG (secondary Ab B), FITC-conjugated Affinipure goat antimouse IgG
(secondary Ab C), and FITC-conjugated Affinipure goat antimouse IgM (sec-
ondary Ab M). All conjugated Abs were obtained from Jackson.
SCCL cell lines DMS79, H146, and H345 were purchased from ATCC.
Cell Culture and Human Tissues
SCCL cell lines were maintained in RPMI 1640  10% FCS, sometimes
supplemented as recommended by ATCC, in a humidified atmosphere of 5%
CO2 and 95% by air at 37°C. Human hypothalamic tissue, frozen in liquid
nitrogen or Tissue-Tek embedded on dry ice, was obtained surgically within 10
min after death.
RNA Isolation
Total RNA was isolated from SCCL cell lines, human hypothalamus, and
Chinese hamster ovary cells using TriPure isolation reagent. To remove
genomic DNA contamination, RNA samples were treated with RNase-free
DNase.
OT and VP RT-PCR and Sequencing
Total RNA (1–5 g) from SCCL cell lines and human hypothalamus
(positive control) was reverse-transcribed in a total volume of 50 l by the
Expand Reverse Transcriptase System using oligo(dT) primer. Reverse tran-
scription products (1:50) were used directly for PCR. PCR was performed with
the Expand Long Template PCR System according to the manufacturer’s
instructions in a UNO II rapid thermocycler (Biometra). After an initial
denaturation step at 94°C for 5 s, reaction mixtures were submitted to 35 cycles
comprising 94°C for 45 s (denaturation), 66°C for 45 s (annealing), and 72°C
for 45 s (elongation). After amplification, an additional extension step at 72°C
for 10 min was performed. The sequences of primers are presented in Table 1.
After migration in 2% agarose gels and staining with ethidium bromide,
RT-PCR transcripts were excised, purified with the QIAquick Gel Extraction
Kit, and sequenced directly by a DNA sequencer (Eurogentec). Reverse
primers used for PCR served as sequencing primers (Table 1).
OTR and VPR RT-PCR and Sequencing
cDNAs were synthesized from total RNA (3 g) of SCCL cell lines and
Chinese hamster ovary cells expressing human V1aR, V1bR/V3R, V2R, and
OTR from transfected plasmids (positive control). The reaction was performed
using Moloney murine leukemia virus reverse transcriptase (200 units) and
random primers as described previously (39). The first-strand synthesis reac-
tion (1:6) was amplified for 30 cycles using Taq polymerase (1 unit) and 100
pmol of each forward and reverse primer (Table 1). Cycling parameters were
94°C for 90 s, 70°C for 90 s, and 72°C for 120 s. Negative control RT-PCR
reactions were performed by omitting reverse transcriptase or RNA from the
reaction mixture. PCR products were separated on a 2% agarose gel and
revealed by ethidium bromide staining. PCR products were subcloned using
pGEM-T easy vector systems (Promega) and sequenced.
OT Binding Assays
Saturation Binding. Incubation was carried out with 2  106 cells/sample
in a final volume of 500 l of assay buffer [DPBS  1% BSA (pH 7.5)] in a
30°C water bath for 1 h. 125I-OVTA (0.005–0.32 nM) was added either without
or with 0.5 M OT, assumed to reflect NSB. The reaction was stopped on an
ice bath, and 2 ml of assay buffer (4°C) were added to each tube before
centrifugation (700  g, 4°C, 10 min). Supernatants were discarded, and
pellets were washed with 10 ml of assay buffer (4°C), followed by an
additional centrifugation step. After removal of the supernatants, pellets were
homogenized with assay buffer (200 l). Each sample was performed in
duplicate; NSB and total binding (BT) values were measured by automatic
gamma counter (Wallac; Perkin-Elmer).
Competitive Displacements. Selectivity of 125I-OVTA binding was as-
sessed by competition studies with various neurohypophysial receptor ligands.
Competitive binding curves were generated with cold OT, OVTA, L-371,257
(OTR antagonist), VP, and F180 (V1aR agonist). Incubation was carried out
with 2 106 cells/sample in a final volume of 500 l of assay buffer in a 30°C
water bath for 1 h. Cold ligand (0–200 nM) was added with 125I-OVTA (0.08
nM). The procedure was ended as reported above.
OT and VP Immunocytochemistry
SCCL cells (0.1  106) were transferred on microscope slides by centrif-
ugation in a cytospin tube (100  g, 10 min.). Cells were fixed successively
by paraformaldehyde (4°C, 20 min) and methanol (20°C, 7 min) and then
incubated for 30 min at room temperature with 10% normal goat serum to
prevent NSB of goat secondary Ab. Single immunostaining was performed
with the following reagents: (a) antihuman CK mAb MNF116 (1:40) followed
by secondary Ab C (FITC-conjugated goat antimouse IgG; 1:40); (b) anti-OT
mAb O33 (1:50) followed by secondary Ab M (FITC-conjugated goat anti-
mouse IgM; 1:40); (c) anti-OT O4 (1:1600) followed by secondary Ab B
(TRITC-conjugated goat antirabbit IgG; 1:50); (d) anti-OT AOS (1:100)
followed by secondary Ab B (TRITC-conjugated goat antirabbit IgG; 1:50);
and (e) anti-VP mAb C2.23 (1:50) followed by secondary Ab C (FITC-goat
antimouse IgG; 1:40). After the final wash, slides were mounted with glycerol/
gelatin medium. Nonspecific staining of secondary Abs (Ab B, C, or M) was
assessed by incubation with buffer [50 mM Tris-HCl and 0.01% NaN3 (pH
7.6)] instead of the first Ab. Nonspecific staining of first Abs was assessed by
replacing the first Ab with equivalent amounts of respective immunoglobulin
isotype controls (mouse IgG1 instead of anti-CK MNF116 and anti-VP C2.23,
mouse IgM instead of anti-OT O33, and rabbit IgG instead of anti-OT O4 and
AOS).
OT and VP-NP Production
DMS79 (1  106 cells/ml), H146 (2  106 cells/ml), and H345 (4  106
cells/ml) cell lines were cultured in 12-well plates. Cells were incubated in 1
ml of RPMI 1640  10% FCS, sometimes supplemented as recommended by
ATCC, in a humidified atmosphere of 5% CO2 and 95% by air at 37°C. Media
and cells were separated every 24 h until 120 h of culture. Incubation medium
aliquots were frozen directly at 20°C, whereas cells were lysed in 500 l of
deionized water and then frozen at20°C. OT enzyme immunoassay (18) and
VP-NP RIA (40) were performed on supernatants and cell contents. RNA was
isolated from cell pellets at each incubation step to perform OT and VP
RT-PCR. LDH was measured, using a standard clinical chemical procedure, to
estimate the rate of living cells at each incubation step. In that view, after
separation of supernatants and cells, cell pellets were lysed with Triton 2% in
RPMI 1640 (900 l). Protease inhibitor (40 l) and glycerol (900 l) were
added to each sample of supernatant and cell solution before storage at20°C.
Table 1 Synthetic primers
Synthetic primers selected for RT-PCR and sequencing of OT (OTf, OTr), VP (VPf,
VPr), OTR (OTRf, OTRr), V1aR (V1af, V1ar), V1bR/V3R (V1bf, V1br), and V2R (V2f,
V2r).
Primer Nucleotide Sequence Strand
Forward
OTf 515–537 5-CGC-CGG-ACC-TCG-ACG-TGC-GCA-A-3 
VPf 1870–1893 5-CGG-CGT-TTG-CTG-CAA-CGA-CGA-GA-3 
OTRf 756–780 5-GGG-CGC-GTG-GCC-CTG-GCG-CGT-GTC-A-3 
V1af 756–782 5-GTC-GCG-CCA-GAG-CAA-GGG-TGC-AGA-GC-3 
V1bf 792–819 5-CGG-GTC-AGC-AGC-ATC-AAC-ACC-ATC-TCA-3 
V2f 653–679 5-CCC-TGG-GTA-TCG-CCG-CCT-GCC-AGG-TG-3 
Reverse
OTr 1162–1187 5-CAT-CAA-AGT-TTC-AGC-GCT-GGG-AGA-A-3 
VPr 2297–2321 5-CGG-AGG-TTT-ATT-GTC-CGT-GCT-GCA-3 
OTRr 1137–1164 5-CGT-GGA-TGG-CTG-GGA-GCA-GCT-CCT-CTG-3 
V1ar 1198–1224 5-GAA-GAT-TTA-GGC-GAG-TCC-TTC-CAC-AT-3 
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Cell Proliferation
Incorporation of [3H]dThd into DNA was measured by liquid scintillation
counting. H345 cells in stock culture were washed in DPBS and replated in
culture flasks (25 cm2) in RPMI 1640 added with 5% charcoaled-FCS (char-
coal treatment discards small molecules and proteins such as OT and VP) and
1% insulin-transferrin-selenium solution at an initial density of 1  105
cells/ml. After 24 h of incubation in a humidified atmosphere of 5% CO2 and
95% O2 at 37°C, OT, OVTA, OT  OVTA, VP, or EGF were added to the
culture medium at final concentrations ranging from 1–100 nM. Each day, 1 ml
of cell suspension was taken and distributed in quadruplicate on 96-well plates
(200 l/well). [3H]dThd (25 l, 11.5 Ci/ml) was added, and plates were
incubated for 4 h in a humidified atmosphere of 5% CO2 and 95% by air at
37°C. Cellular DNA was harvested from the cells using a Titertek cell
harvester (Flow Laboratories). One-min sample counts were obtained in a
Beckman liquid scintillation counter (Beckman).
Statistical Analyses
Binding assays were analyzed with GraphPad Prism software, using a one
site binding (hyperbola) model or a one site competition model without
weighting method.
Proliferation curves were analyzed with GraphPad Prism software, using
ANOVA followed by Student-Newmaan-Keuls test.
RESULTS
RT-PCR and Sequencing. Total RNA preparations from SCCL
cell lines DMS79, H146, and H345 and hypothalamus (positive con-
trol) were used in RT-PCR studies to generate products representing
OT mRNA and VP mRNA. In each case, a cDNA product of the
expected size (OT, 288 bp; VP, 258 bp) was obtained (Fig. 1A).
Transcript sizes were predicted from GenBank sequence HUMOTNPI
(G189414) for the human prepro-oxytocin-NP gene and GenBank
sequence HUMVPNP (G340302) for the human prepro-8-arginin-NP
gene. Sequencing of OT and VP PCR products confirmed the speci-
ficity and selectivity of the OT and VP primers. Each primer set fits
with mRNA regions corresponding to minimal sequence similarity
between OT and VP. Indeed, each PCR product presents 90–99%
homology compared with their respective GenBank sequence.
Four different primer sets were used to amplify OTR, V1aR,
V1bR/V3R, and V2R. In all pairs, the position of the oligonucleotides
fitted with a region corresponding to minimal homology between
OTR and different VPR. Moreover, the priming sites were separated
by an intron, thus distinguishing products from cDNA from those
generated through any contaminating genomic DNA (for OTR, V1aR,
and V1bR/V3R) or genomic amplification with a different size than
the cDNA product (for V2R; data not shown). As shown in Fig. 1B,
a single product of the expected size (408, 468, and 254 bp) was
amplified in each of the SCCL cell lines for OTR, V1aR, and V1bR/
V3R, respectively. No amplification of V2R (437 bp) mRNA was
Fig. 2. OTR binding on H345. A, hyperbolic analysis of saturation binding with
125I-OVTA. Data are expressed as a function of bound 125I-OVTA (pM)  SD (B
125I-OVTA  BT  NSB [concentration of radioactive ligand binding]) versus 125I-
OVTA (nM) added. B, Scatchard analysis of H345 saturation binding with 125I-OVTA.
Data are expressed as a function of B/F ratio between radioactive ligand bound and free
ligand  SD versus B 125I-OVTA (pM). C, competitive displacement of 125I-OVTA with
OVTA (OTR antagonist; f), OT (Œ), L-371,257 (OTR antagonist; ), F180 (V1aR
agonist;), and VP (F). Data are expressed as a function of B/B0 (%)  SD, versus log
(ligand) (M, molar).
Fig. 1. OT, VP, and receptor RT-PCR. A, OT and VP RT-PCR products obtained from
total RNA preparation of human hypothalamus (Lane 1) and SCCL cell lines DMS79
(Lane 2), H146 (Lane 3), and H345 (Lane 4). H2O was used as negative control (), and
Lane M represents the molecular weight marker. B, RT-PCR products of OTR (Lanes 5,
9, 13, and 17), V1aR (Lanes 6, 10, 14, and 18), V1bR/V3R (Lanes 7, 11, 15, and 19), and
V2R (Lanes 8, 12, 16, and 20) obtained from total RNA preparation of SCCL cell lines
H345, DMS79, and H146 and from CHO cells expressing human V1aR, V1bR/V3R,
V2R, and OTR from transfected plasmids (positive control,). H2O was used as negative
control () respectively for OTR (lane 1), V1aR (lane 2), V1bR/V3R (lane 3) and VeR
(lane 4). Selected primers yielded cDNAs of 408 (OTR), 468 (V1aR), 254 (V1bR/V3R),
and 437 (V2R) bp.
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observed for SCCL cell lines, even though a product of 437 bp was
amplified in the positive control. Oligonucleotide sequences of each
amplified fragment correspond to OTR, V1aR, and V1bR/V3R se-
quences described by Kimura et al. (41), Thibonnier et al. (42), and
Sugimoto et al. (43).
OT Binding Assays. Binding of 125I-OVTA is observed in SCCL
cell lines H345 (Fig. 2) DMS79, and H146 (data not shown). Depend-
ing on the analytical method (hyperbola or Scatchard), Kd ranges from
0.025–0.06 nM for DMS79 cells and from 0.037–0.089 nM for H146
cells. Both analyses give similar Kd values (0.065 and 0.07 nM) for
H345 cells. Saturation bindings with 125I-OVTA exhibit Kd values of
the same order for the three SCCL cell lines. On the contrary, the
estimated number of binding sites per million cells is about 10 times
higher for H345 cells than for H146 and DMS79 cells. Indeed,
1.10–1.18 fmol/million cell binding sites (depending on analysis
method) are deduced from Bmax (maximal bindings value) for H345
cells, whereas there is 0.15–0.20 fmol/million DMS79 cells binding
sites, and 0.10–0.15 fmol/million H146 cells binding sites. Charac-
terization of the receptor evidenced by saturation binding with 125I-
OVTA has been investigated by displacement with various ligands.
On H345 cells, OVTA (OTR antagonist), OT, and L-371,257 (OTR
antagonist) displace 125I-OVTA in a similar manner with an average
EC50 of 0.57  0.14 (SD) nM. Displacements observed with VP and
F180 (V1aR agonist) do not reach 50% B/Bo, even if ligand concen-
trations are 200 nM. If ligand is used at 1 nM, the average displacement
obtained with OVTA, OT, and L-371,257 is 42.1% B/Bo, whereas it
is 90.7% B/Bo with F180 and 79.5% B/Bo with VP. For DMS79 cells,
a preponderant displacement is observed with OTR ligands
(OVTA L-371,257 OT). Displacements with VP and F180 never
exceed 40% B/Bo. For H146 cells, similar displacement curves are
observed with OVTA, L-371,257, OT, and VP. However, F180 dis-
placement remains over 60% B/Bo even when the ligand concentra-
tion used is 200 nM.
OT and VP Immunocytochemistry. Fig. 3 shows the staining
obtained with anti-CK (MNF116) and anti-VP (C2.23) on H345, as
well as the staining obtained with anti-OT (O33) on DMS79. Similar
labeling was observed with other anti-OT Abs (O4 and AOS), and
comparable results were obtained for all three different SCCL cell
lines studied (data not shown). Staining obtained with anti-CK dem-
onstrates the epithelial phenotype of SCCL cells. Distinct spots are
observed with anti-OT mAb O33, whereas a more diffuse labeling is
observed with anti-VP mAb C.2.23. No staining is observed in the
nucleus of cells; the crown-like staining obtained with anti-neurohy-
pophysial peptide Abs seems to correlate with cytoplasm and cell
membrane localization.
OT and VP Production. IR OT and IR VP-NP were measured in
cell contents, as well as in supernatants of H345 cells cultured for a
total period of 120 h. Expression of VP and OT mRNA and LDH
levels were established for each incubation step. Data for IR OT has
been presented elsewhere (18). IR OT measurement in supernatants
ranged from 5–40 pg/ml, and the relative IR OT cellular fraction
ranged from 6.5–14 pg/106 H345 cells. Similar results were obtained
for DMS79 and H146 cells, but in these SCCL cell lines, the relative
IR OT cellular fraction seemed to be significantly higher than the
H345 one. Indeed, IR OT measurement in supernatants was in
the same range of concentration for the three cell lines, whereas the
relative IR OT cellular fraction ranged from 32.5–70 pg/106 cells for
H146 and 65–140 pg/106 cells for DMS79. IR VP-NP levels are
presented in Fig. 4A, and a maximal secretion of 3.2 ng/ml is meas-
ured after 96 h of incubation. Hormone production is concomitant
with OT and VP mRNA production (Fig. 4B). LDH quantification
shows a constant number of living H345 cells (4 106 cells) during
the whole culture procedure (Fig. 4C).
OT Effect on Cell Growth. The effect of OT on H345 cellular
proliferation was evaluated by [3H]dThd incorporation assays (Fig. 5).
After 48 h of OT treatment, a significant increase in cell proliferation
was observed, compared with the control curve, with 1 nM OT (,
P  0.01) and 100 nM OT (, P  0.001; Fig. 5A). The mitogenic
effect of exogenous OT was dose dependent and time persistent.
Indeed, the incubation with 1 nM OT showed a growth increase
ranging from 18–25%, and the effect of 100 nM OT was from
28–58%. When cells were incubated with a mix of OVTA (1 nM) and
OT (1 nM), the OT mitogenic effect was completely abolished, and the
proliferation profile was maintained in the range of the control curve.
A significant reduction of cell growth (, P  0.001) was detected
after 24 h of OVTA (1 nM, OTR antagonist) treatment. This decrease
Fig. 3. OT and VP immunocytochemistry. H345 cells are
labeled by fluorescence immunostaining with antihuman CK
mAb MNF116 (CK) and anti-VP mAb C2.23 (VP). Immunola-
beling with anti-OT mAb O33 [OT (O33)] is presented on
DMS79. Labeling with anti-OT O4 and AOS exhibits similar
staining (data not shown). For all Abs tested, similar results
were obtained with the three SCCL cell lines studied (data not
shown). Control OT and control VP represent nonspecific stain-
ing for anti-OT O33 and anti-VP C2.23, respectively. It is
obtained by replacing the first Ab with IgM and IgG1 isotype
controls, respectively.
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of cell proliferation was observed at all time points (, P  0.001)
and ranged from 33–48%. VP (1 nM) and EGF (8 nM) stimulation was
used as positive control (Fig. 5B). A significant mitotic effect ap-
peared after 48 h of treatment (, P 0.001), ranging from 24–49%.
The increase in cell proliferation induced by exogenous OT is in the
same order of magnitude as the one induced by VP or EGF.
DISCUSSION
Although the expression of all known VP receptors (V1aR, V1bR/
V3R, and V2R) has already been reported in SCCL (17), the expres-
sion of OTR has never been investigated in SCCL cell lines. Our data
clearly demonstrate that OTR mRNA is detected in three SCCL cell
lines. Binding of 125I-OVTA is observed on all SCCL cell lines
studied, with a Kd ranging from 0.025–0.089 nM, depending on the
cell line and the analytical method. These values correspond to the
characteristics of 125I-OVTA binding to mammary tissue, uterus, and
testis (44). The selectivity of 125I-OVTA binding is confirmed by the
results of displacements observed with various OTR and VPR ago-
nists and antagonists. For H345 cells, parallel and equal displacements
are observed with OVTA, OT, and L-371,257 (OTR antagonist),
whereas VP and F180 (V1aR agonist) show a very poor displacement
of 125I-OVTA. Indeed, VP and F180 displacement curves are shifted
to the right and do not reach 50% B/Bo when OVTA, OT, and
L-371,257 curves exhibit a complete displacement. These data iden-
tify the neurohypophysial binding site present at the H345 cell surface
as true OTR. For DMS79 and H146 cells, the binding site density is
about 10 times lower than that for H345 cells. The order of binding
affinity for DMS79 was OVTA  L-371,257  OT  VP 
F180. For H146, similar displacements were observed with OVTA,
OT, L-371,257 and VP, whereas only F180 exhibited very low affin-
ity. The variations observed between these displacement profiles
could result from various OTR densities or could be due to the
concomitant presence of VPR, as shown by RT-PCR and competitive
binding analyses. As a matter of fact, V1aR and V1bR/V3R mRNAs
were also identified in concordance with previous studies (17). How-
ever, with the primers and the experimental conditions used in this
study, we were unable to observe V2R mRNA amplification, although
Fig. 5. Effect of OT on H345 cell proliferation. Proliferation of H345 was estimated by
[3H]dThd incorporation normalized for each sample at 100% at time  24 h, before the
addition of OT, OVTA, VP, or EGF. Data are expressed as growth percentage  SD
versus time (h). In both graphs,   P  0.01 and   P  0.001 (OT, VP, or EGF
versus control), and the cutoff for significance is 0.05. A, H345 proliferation curves under
control condition (f), with exogenous 1 nM OT (F) or 100 nM OT (E) treatment, with 1
nM OVTA (), or with a mixture () of 1 nM OT and 1 nM OVTA. OT, OVTA, or the
mixture is added at time  24 h. B, H345 proliferation curves under control condition (f)
and with 1 nM VP () or 8 nM EGF (Œ) treatment. VP and EGF are added at time 24 h.
Fig. 4. VP-NP and OT release. A, histogram represents IR VP-NP concentrations
(expressed in ng/ml  SD) measured by RIA in supernatants (A) and cell contents (B) of
SCCL cell line H345 at each incubation step: 24 h (f), 48 h (), 72 h (gray box), 96 h
(dotted box), and 120 h (o). The total OT and VP-NP production (C) was calculated from
A  B. B, VP and OT RT-PCR products (258 and 288 bp, respectively) obtained from
total RNA preparation of H345 isolated at each incubation step: 24 h (Lane 1); 48 h (Lane
2); 72 h (Lane 3); 96 h (Lane 4); and 120 h (Lane 5). H2O was used as negative control
(), and Lane M represents the molecular weight marker. C, graph represents the number
of H345 living cells, expressed as million SD, during the whole culture procedure (from
24 h up to 120 h). The number of living cells was evaluated from LDH measurement in
supernatants and cell extracts at each incubation step.
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North et al. (17) have previously demonstrated the presence of this
receptor in SCCL cells. Nevertheless, our observations strongly sup-
port the expression of OTR by H345, DMS79, and H146 SCCL cell
lines. In particular, the cell line H345 seems to be a very appropriate
model for additional studies about OTR expression in SCCL.
The presence of IR OT has been reported previously in acetone
extracts of SCCL tumors (5). In the present study, OT synthesis and
release by SCCL cells expressing OTR were further investigated. The
presence of OT transcripts was evidenced by RT-PCR with a novel set
of specific primers, designed and controlled on human hypothalamus
mRNA. The identification of IR OT was performed using fluores-
cence immunocytochemistry with three different Abs. Our experi-
ments demonstrate an endogenous OT peptide synthesis. The release
of OT has been quantified on H345, DMS79, and H146 cells by OT
enzyme immunoassay (18). The variations in total OT levels during
the whole culture could reflect a balance between its synthesis/
secretion and enzymatic degradation, which could be influenced dur-
ing autocrine/paracrine signaling. Continuous OT production during
the whole culture is confirmed by OT RT-PCR on mRNA cell
extracts. The characterization of the neurohypophyseal peptide system
in these SCCL cells includes VP expression (as shown by RT-PCR)
and VP-NP secretion (which reflects the amount of VP released by
SCCL cells). The experiments have been performed in such a way that
VP and OT synthesis and release could be compared. Our results show
that both OT and VP are concomitantly synthesized and released by
the three SCCL cell lines investigated, even though in the hypothal-
amus, these peptides are synthesized by distinct neurons (45). Thus, in
the limits of cell line biology, our data clearly demonstrate that, in
addition to the VP system, OT and OTR are also implicated in SCCL
biology.
In a recent editorial (46), Bussolati and Cassoni emphasized the
complexity of the OT/OTR system in physiology and pathophysiol-
ogy. In breast cancer, in vitro effects of OT on cell proliferation vary
from antiproliferative to mitogenic (26, 28, 47, 48). In choriocarci-
noma, OT promotes cell growth (30), whereas it decreases prolifera-
tion of glial tumors, endometrial adenocarcinomas, and neuroblasto-
mas (23, 27). Neurohypophysial peptides were also shown to exert
mitogenic effects on freshly isolated immature T cells (thymocytes;
Ref. 49). In our experiments, we observed a mitogenic effect of
exogenous OT on H345 cell proliferation. This effect, tested at 1 and
100 nM, was dose dependent and time persistent. It was already
significant (P  0.01) after a 48-h incubation with 1 nM OT, which is
an efficient and physiological value to activate OTR. This mitogenic
effect of exogenous OT (1 nM) was abolished by 1 nM OVTA,
demonstrating that the increase of proliferation observed was really
induced by OT. The effect of endogenous OT was assessed by
incubating the cells with 1 nM OVTA alone. The inhibition of cell
proliferation obtained under these conditions strongly supports a
mitogenic action of the OT secreted by the SCCL cells. Such an effect
of OT that mimics a growth factor was also recently suggested to be
involved in a study on Kaposi’s sarcoma cells (50) as well as when
OTR presents a caveolar localization (51).
In conclusion, the present study demonstrates concomitant OT
synthesis and secretion, as well as OTR expression, by three distinct
human SCCL cell lines. Moreover, we observed an exogenous as well
as an endogenous OT-induced increase in SCCL proliferation. The
clinical significance of these findings is currently being investigated
in human patients with this type of lung cancer. Nevertheless, immu-
notherapy toward tumor-derived OT or OT-NP already appears as a
valuable new perspective not only for the treatment of SCCL patients
with poor response to chemotherapy and radiotherapy-resistant dis-
ease but also for all patients expressing OTR. Finally, our results
suggest that OT antagonists may offer promise as a potential new
therapeutic modality for the treatment of SCCL.
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